Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6274 posts found.

volodymyr-hryshchenko-m1hq4ibp9rc-unsplash

FDA grants ODD to Revolo Biotherapeutics’ eosinophilic esophagitis treatment

February 1, 2024 Medical Communications FDA, ODD, Pharmacy, Revolo Biotherapeutics, eosinophilic esophagitis

Revolo Biotherapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ‘1104, …
News

MHRA approves GSK’s Omjjara in Great Britain for splenomegaly treatment

January 31, 2024 Medical Communications GSK, MHRA, Omjjara, Oncology, myelofibrosis, splenomegaly

GSK has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Omjjara (momelotinib) in …
News

EMA to review GSK’s Arexvy for RSV prevention in adults aged 50-59

January 29, 2024 Medical Communications Arexvy, EMA, Infections and infestations, RSV

GSK has announced that the European Medicines Agency (EMA) has accepted the company’s regulatory application to expand the use of …
News

MHRA approves Mounjaro for diabetes and weight management

January 26, 2024 Medical Communications Diabetes, MHRA, Mounjaro, weight management

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced that it has approved a four-dose version of the diabetes …
News

Haleon recalls cough syrups due to microbial contamination

January 25, 2024 Medical Communications Haleon, Pharmacy, cough syrup, microbial contamination

The US Food and Drug Administration (FDA) has shared an announcement from Haleon detailing the voluntary recall of eight lots …
News

Alphamab Oncology and 3DMedicines enter licensing agreement with Glenmark Speciality

January 25, 2024 Medical Communications 3DMedicines, Alphamab Oncology, Glenmark Speciality, Oncology, envafolimab

Alphamb Oncology and 3DMedicines have announced that they have entered into a license agreement with Glenmark Speciality, a subsidiary of …
News

UKHSA warns of measles outbreak

January 22, 2024 Medical Communications Infections and infestations, MMR, UKHSA, measles, vaccination

The UK Health Security Agency (UKHSA) has warned that further outbreaks of measles could spread to other towns and cities …
News

FDA approves Balversa for bladder cancer treatment

January 22, 2024 Medical Communications Balversa, FDA, Johnson & Johnson, Oncology, bladder cancer

Johnson & Johnson (J&J) have announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug …
News
anirudh-djo3injpaoe-unsplash_3

AstraZeneca’s Voydeya approved in Japan for PNH treatment

January 19, 2024 Medical Communications AstraZeneca, Haematology, PNH, Voydeya

AstraZeneca has announced that Voydeya (danicopan) has been approved in Japan for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), in …
News

Verastem Oncology gains Fast Track Designation for combination NSCLC treatment

January 19, 2024 Medical Communications Cancer, FDA, NSCLC, Oncology, Verastem Oncology

Verastem Oncology has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation to the company’s …
News

FDA clears DermaSensor’s AI detection device for skin cancer

January 18, 2024 Medical Communications FDA, Oncology, skin cancer

DermaSensor has announced that the US Food and Drug Administration (FDA) has granted clearance for its real-time, non-invasive skin cancer …
News

Arcus Biosciences shares results from phase 1b trial for pancreatic cancer treatment

January 18, 2024 Medical Communications Arcus Biosciences, Oncology, Pancreatic cancer, clinical trial

Arcus Biosciences has announced new data from the ARC-8 phase 1b clinical study which is being co-developed alongside Gilead Sciences. …
News

FDA approves Merck’s Keytruda with chemoradiotherapy as cervical cancer treatment

January 15, 2024 Medical Communications FDA, Oncology, cervical cancer, keytruda

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
News

NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19

January 12, 2024 Medical Communications COVID-19, Infections and infestations, NICE

The National Institute for Health and Care Excellence (NICE) has announced that it has expanded the guidance around which patients …
News

Santhera gains MHRA approval for Agamree as treatment for Duchenne muscular dystrophy

January 12, 2024 Medical Communications Agamree, Duchenne Muscular Dystophy, MHRA, Musculo-skeletal disorder, santhera

Santhera Pharmamceuticals has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Agamree (vamorolone) in the UK …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024